US6960775020 - Common Stock
PALATIN TECHNOLOGIES INC
NYSEARCA:PTN (5/3/2024, 7:13:58 PM)
After market: 2 -0.11 (-5.21%)2.11
+0.06 (+2.93%)
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 34 full-time employees. The firm is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. The company is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. The company has completed Phase III PL9643 clinical study for dry eye disease. The company is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.
PALATIN TECHNOLOGIES INC
4B Cedar Brook Drive
Cranbury NEW JERSEY 08512
P: 16094952200
CEO: Carl Spana
Employees: 34
Website: https://www.palatin.com/
Palatin Technologies (PTN) stock plunged 40% Wednesday after the company said a Phase 3 pivotal study for its drug PL9643 failed to meet a co-primary endpoint. Read more here.
With proposed FED rate cuts incoming, these are the penny stocks that are likely to see a spark into new rallies.
Although true 10-baggers are by nature extremely difficult to come by, these analyst-backed stocks may offer a decent shot.
Palatin (PTN) announces a registered direct offering of approximately 1.83 million shares at $5.46 per share, alongside a concurrent private placement of...
These penny stocks have triple-digit upside as 2024 brings easing monetary policy and economic normalization.
Here you can normally see the latest stock twits on PTN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: